Biohaven: Despite Troriluzole Program Delay, FDA Review On Track For Q4 2025

Biohaven's troriluzole has demonstrated a 50-70% slowing of Spinal Cerebellar Ataxia (SCA) disease progression, with its FDA review now slated for Q4 2025. The FDA's decision to forgo an advisory committee meeting streamlines the approval pathway for this versatile drug, which is effective across all SCA genotypes and faces no FDA-approved market competition. This positions troriluzole as a compelling investment opportunity within the global SCA market, projected to reach $706.72 million by 2033.

Analysis

Biohaven's lead asset for Spinal Cerebellar Ataxia (SCA), troriluzole, has experienced a significant de-risking event following the FDA's decision to forgo an advisory committee meeting for its review. This development streamlines the path to a potential approval, which is now targeted for Q4 2025. The regulatory confidence is likely supported by clinical data demonstrating a 50% to 70% slowing of disease progression. Critically, troriluzole is positioned as a first-in-class therapy, as there are no currently FDA-approved competitors for SCA, and its versatility across all SCA genotypes expands its addressable patient population. This provides Biohaven a potential first-mover advantage in the global SCA market, which is forecast to reach $706.72 million by 2033.

Key Decisions for Investors

• Given the significant de-risking from the FDA's waiver of an advisory committee and the strong efficacy data, investors could view the Q4 2025 PDUFA date for troriluzole as a primary upcoming catalyst for Biohaven.
• The primary remaining hurdle is the binary outcome of the final FDA approval decision, meaning positions should be sized to account for this risk, while monitoring for any further regulatory communications.
• Investors should model the potential revenue from the projected $706.72 million SCA market against Biohaven's current valuation to determine the potential impact of a successful commercial launch.